公众号 / 文章消化、代谢与肾脏急症中毒与环境急症

药物性肝损伤的新型生物标志物

Novel biomarkers for drug-induced liver injury.
PubMed 文献 · Clin Toxicol (Phila) · 2023-10-10
一句话结论丙氨酸转氨酶(ALT)和天冬氨酸转氨酶(AST)诊断已确立的药物性肝损伤(DILI)表现良好,但可能缺乏特异性且无预后价值;角蛋白-18、谷氨酸脱氢酶、microRNA-122等是主要候选新型标志物,尚需在醋氨酚过量等急性肝损伤风险患者中经严格临床试验验证。

本文为综述,概述药物性肝损伤(DILI)的机制及新兴生物标志物。当前金标准标志物丙氨酸转氨酶(ALT)和天冬氨酸转氨酶(AST)在诊断已确立的DILI时表现良好,但可能缺乏特异性且无预后价值;ALT和胆红素是广泛使用并经数十年临床经验验证的标志物。新型标志物的证据要求取决于其使用场景,特别是假阴性或假阳性结果对患者结局的影响。主要候选标志物包括角蛋白-18、谷氨酸脱氢酶、microRNA-122、高迁移率族蛋白B1、骨桥蛋白和巨噬细胞集落刺激因子受体1。新型标志物可能有助于早期检测DILI、解读ALT活性升高以及临床试验中的剂量递增决策;挑战在于在醋氨酚过量等急性肝损伤风险患者中临床验证领先候选标志物,需严格临床试验,若要广泛采用需明确证明在总费用、发病率或死亡率方面的获益。

要点

  • ALT和AST在诊断已确立的DILI时表现良好,但可能缺乏特异性且无预后价值。
  • ALT和胆红素是广泛使用且经数十年临床经验验证的DILI标志物。
  • 新型标志物的证据要求取决于使用场景,特别是假阴性或假阳性结果对患者结局的影响。
  • 主要候选新型标志物包括角蛋白-18、谷氨酸脱氢酶、microRNA-122、高迁移率族蛋白B1、骨桥蛋白和巨噬细胞集落刺激因子受体1。
  • 新型标志物可能有助于早期检测DILI、解读ALT活性升高以及临床试验中的剂量递增决策;需在醋氨酚过量等急性肝损伤风险患者中经严格临床试验验证,并明确证明在总费用、发病率或死亡率方面的获益。

适用人群与场景

  • 因药物导致肝毒性(药物性肝损伤)的患者,是临床医生和药物开发者的挑战。
  • 醋氨酚过量等有急性肝损伤风险的患者。

研究设计与关键结果

  • 综述指出:丙氨酸转氨酶(ALT)和天冬氨酸转氨酶(AST)活性在诊断已确立的药物性肝损伤时表现良好,但可能缺乏特异性且无预后价值。
  • 综述指出:ALT和胆红素是广泛使用且经数十年临床经验验证的药物性肝损伤标志物。
  • 综述指出:新标志物所需证据量取决于其使用场景,特别是假阴性或假阳性结果对患者结局的影响。
  • 综述列举主要候选标志物:角蛋白-18、谷氨酸脱氢酶、microRNA-122、高迁移率族蛋白B1、骨桥蛋白和巨噬细胞集落刺激因子受体1。
  • 综述指出:新型标志物可能有助于早期检测药物性肝损伤、解读ALT活性升高以及临床试验中的剂量递增决策。
  • 综述指出:已有大量探索性研究描述生物标志物差异及其在风险分层或识别现有评估方案可能失败的患者中的潜在价值;使用探索性标志物指导临床试验决策正变得常规。

证据类型、等级与局限

  • 证据类型:综述。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 综述指出:ALT和AST在诊断已确立的DILI时表现良好,但可能缺乏特异性且无预后价值。
  • 综述指出:新型标志物可能有助于早期检测DILI、解读ALT活性升高以及临床试验中的剂量递增决策;目前仍处于探索性研究阶段,尚未常规用于临床。
  • 综述指出:挑战在于在醋氨酚过量等急性肝损伤风险患者中临床验证领先候选标志物,需严格临床试验;若要广泛采用需明确证明在总费用、发病率或死亡率方面的获益。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

INTRODUCTION: Liver toxicity due to medicines (drug-induced liver injury) is a challenge for clinicians and drug developers. There are well-established biomarkers of drug-induced liver injury, which are widely used and validated by decades of clinical experience. These include alanine aminotransferase and bilirubin. Limitations of the current biomarkers are well described, and this has resulted in global efforts to identify and develop new candidates. This process has been aided by regulatory pathways being established for biomarker qualification. This article aims to provide a broad overview of the mechanisms of liver toxicity and discuss emerging novel biomarkers. There is a focus on the recent advances in the identification and validation of novel biomarkers, their potential applications in drug development and clinical practice, and the challenges and opportunities in translating these biomarkers into routine clinical use.

CURRENT GOLD-STANDARD BIOMARKERS: Alanine and aspartate aminotransferase activities perform well in diagnosing established drug-induced liver injury but may lack specificity and are not prognostic.

THE BURDEN OF PROOF FOR NOVEL BIOMARKERS: The amount of evidence required for a new biomarker will depend on its context-of-use, specifically on the impact on patient outcome of a false negative or false positive result.

LEADING POTENTIAL BIOMARKERS: Cytokeratin-18, glutamate dehydrogenase, microRNA-122, high-mobility group box 1 proteins, osteopontin, and macrophage colony-stimulating factor receptor 1 are examples of lead candidates.

POTENTIAL APPLICATIONS OF NOVEL BIOMARKERS: The early detection of drug-induced liver injury, interpretation of an alanine aminotransferase activity increase, and decisions about dose escalation in clinical trials may all be informed by new biomarkers.

CONCLUSIONS: There have been numerous exploratory studies describing differences in biomarkers and their potential value in risk-stratifying populations or identifying specific patients who may be failed by current assessment protocols. Additionally, the use of exploratory biomarkers to guide clinical trial decision-making is becoming routine. The challenge is now clinically validating leading candidate biomarkers in the assessment of patients presenting with conditions such as paracetamol overdose, which place them at risk of acute liver injury. This will require robust clinical trials. If the use of these biomarkers is to be widely adopted, they will need to unequivocally demonstrate benefit in overall cost, morbidity or mortality.

来源:Clin Toxicol (Phila),查看原文。版权归原作者所有。

参考来源

  1. Humphries C, Dear JW. Novel biomarkers for drug-induced liver injury. Clin Toxicol (Phila). 2023. PMID: 37767912. doi:10.1080/15563650.2023.2259089

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。